GlycoMimetics Inc at Stifel Virtual Healthcare Conference Transcript
My name is Ellen Sands, and I'm a biotechnology associate at Stifel. And today, I have the pleasure of speaking with Rachel King, the CEO of GlycoMimetics. (Operator Instructions)
So Rachel, thanks for being here today, and...
Sure.
And maybe to start, you can give a brief overview of GlycoMimetics and just touch on the pipeline at a high level, and then we can dive in after that.
Sure. So we're a clinical stage company. We've got a late-stage program now in AML, which is in 2 Phase III registration trials, one is treating newly diagnosed patients who are fit for chemotherapy, and the other treating relapsed/refractory patients also fit for chemotherapy. That's our most advanced program.
We also have a program that recently
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
